COMMUNIQUÉS West-GlobeNewswire

Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook
06/11/2025
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP [...]
Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook
06/11/2025
Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year period Third Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year period Adjusted EBITDA for Q3 [...]
Teleflex Announces Quarterly Dividend
06/11/2025
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The [...]
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
06/11/2025
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of [...]
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase [...]
Pow.Bio, Bühler, and ATV Technologies Announce Major Advancement in Continuous Biomanufacturing with 3,000-Liter Scale Success
06/11/2025
ALAMEDA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pow.Bio, the pioneer in continuous biomanufacturing, Bühler Group, the global solutions provider for food, feed, and advanced materials, and ATV Technologies, the [...]
WeightWatchers Announces Third Quarter 2025 Results
06/11/2025
End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net [...]
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
06/11/2025
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori [...]
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
06/11/2025
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to [...]
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
06/11/2025
Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key [...]
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
06/11/2025
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for planned adaptive [...]
Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
06/11/2025
Initiated full U.S. commercial launch of AYON Body Contouring System ™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations Submitted new 510(k) for AYON for device label expansion to include [...]
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
06/11/2025
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline results expected [...]
Opus Genetics Announces $23 Million Registered Direct Offering
06/11/2025
- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2025 (GLOBE [...]
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
06/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
06/11/2025
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings [...]
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
06/11/2025
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome MIAMI, [...]
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of [...]
Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
06/11/2025
Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead [...]

Pages